Biolidics to acquire Biomedics Laboratory for up to S$3.7m
CANCER-diagnostics company Biolidics has entered an agreement to acquire Biomedics Laboratory from SAM Laboratory, a subsidiary of Clearbridge Health, for a cash consideration of up to S$3.7 million.
This acquisition will give Biolidics immediate access to Biomedics Laboratory's resources and capabilities, said Biolidics in a statement on Friday.
Under the agreement, Biolidics will pay S$100,000 upon completion of the acquisition; the remaining consideration can be deferred for up to 24 months. If Biolidics makes payment within 12 months upon completion of the acquisition, the total consideration of the acquisition shall be less - S$3.5 million.
In relation to the acquisition, Biolidics said that it will continue to collaborate with Clearbridge to tap its customer base by entering a distribution-services agreement with Clearbridge Medical Group to distribute diagnostics tests.
The acquisition and distribution-services agreements are subject to the approval of Biolidics' shareholders at an extraordinary general meeting, to be convened in due course.
The company has appointed Xandar Capital as the independent financial adviser.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Biolidics shares closed up 4.6 per cent at S$0.21 on Friday.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
China’s top airlines improve balance sheet in Q1; outlook positive for May Day
Stablecoin issuer Tether invests US$200 million in brain-computer interface company
Yahoo to lay off staff in Singapore as it shifts to content curation
US: Wall St opens higher on megacap strength, Fed verdict awaited
IReit Global occupancy rate grows to 91.5% in Q1
Yen surges against US dollar on suspected intervention